465 related articles for article (PubMed ID: 12478815)
21. The kinetics of plasmin inhibition by aprotinin in vivo.
Kang HM; Kalnoski MH; Frederick M; Chandler WL
Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
[TBL] [Abstract][Full Text] [Related]
22. [Activation of fibrynolysis in children with chronic B or C hepatitis].
Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
[TBL] [Abstract][Full Text] [Related]
23. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
[TBL] [Abstract][Full Text] [Related]
24. Hypercoagulability existing in the local left atrium of patient with mitral stenosis.
Wang J; Xie X; He H; Huang J; Lu D; Yang Q
Chin Med J (Engl); 2003 Aug; 116(8):1198-202. PubMed ID: 12935411
[TBL] [Abstract][Full Text] [Related]
25. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
Agren A; Wiman B; Schulman S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
[TBL] [Abstract][Full Text] [Related]
26. Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study.
Naumnik B; Pawlak K; Mys'liwiec M
Clin Appl Thromb Hemost; 2009 Feb; 15(1):84-91. PubMed ID: 17895513
[TBL] [Abstract][Full Text] [Related]
27. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG
Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
[TBL] [Abstract][Full Text] [Related]
28. Plasma PAI-1 levels are independently related to fatty liver and hypertriglyceridemia in familial combined hyperlipidemia, involvement of apolipoprotein E.
Brouwers MC; Govers-Riemslag J; Schalkwijk CG; van Greevenbroek MM; van der Kallen CJ; Bekers O; van Dieijen-Visser MP; Ten Oever J; Bilderbeek-Beckers MA; de Bruin TW; Ten Cate H; Stehouwer CD
Thromb Res; 2008; 122(4):466-72. PubMed ID: 18262228
[TBL] [Abstract][Full Text] [Related]
29. Elastase- and plasmin-mediated fibrinolysis in rheumatoid arthritis.
Carmassi F; De Negri F; Morale M; Puccetti R; Chung SI
Int J Tissue React; 1994; 16(2):89-93. PubMed ID: 7960505
[TBL] [Abstract][Full Text] [Related]
30. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis.
Blann AD; Dobrotova M; Kubisz P; McCollum CN
Thromb Haemost; 1995 Aug; 74(2):626-30. PubMed ID: 8584997
[TBL] [Abstract][Full Text] [Related]
31. Thrombogenesis in sickle cell disease.
Tomer A; Harker LA; Kasey S; Eckman JR
J Lab Clin Med; 2001 Jun; 137(6):398-407. PubMed ID: 11385360
[TBL] [Abstract][Full Text] [Related]
32. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
33. Hypertriglyceridemia, but not hypercholesterolemia, is associated with the alterations of fibrinolytic system.
Hiraga T; Shimada M; Tsukada T; Murase T
Horm Metab Res; 1996 Nov; 28(11):603-6. PubMed ID: 8960902
[TBL] [Abstract][Full Text] [Related]
34. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
35. Changes in haemostatic factors and activation products after exercise in healthy subjects with different ages.
van den Burg PJ; Hospers JE; van Vliet M; Mosterd WL; Bouma BN; Huisveld IA
Thromb Haemost; 1995 Dec; 74(6):1457-64. PubMed ID: 8772220
[TBL] [Abstract][Full Text] [Related]
36. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.
Bellucci S; Ignatova E; Jaillet N; Boffa MC
Thromb Haemost; 1993 Nov; 70(5):736-42. PubMed ID: 8128427
[TBL] [Abstract][Full Text] [Related]
37. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
Ludwig S; Dharmalingam S; Erickson-Nesmith S; Ren S; Zhu F; Ma GM; Zhao R; Fenton JW; Ofosu FA; Velthuis HT; van Mierlo G; Shen GX
Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
[TBL] [Abstract][Full Text] [Related]
38. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
[TBL] [Abstract][Full Text] [Related]
39. Prospective double-arm study of fibrinolysis in surgical patients.
Kosir MA; Schmittinger L; Barno-Winarski L; Duddella P; Pone M; Perales A; Lange P; Brish LK; McGee K; Beleski K; Pawlak J; Mammen E; Sajahan NP; Kozol RA
J Surg Res; 1998 Jan; 74(1):96-101. PubMed ID: 9536981
[TBL] [Abstract][Full Text] [Related]
40. Quantitative and temporal differences in coagulation, fibrinolysis and platelet activation after on-pump and off-pump coronary artery bypass surgery.
Vallely MP; Bannon PG; Bayfield MS; Hughes CF; Kritharides L
Heart Lung Circ; 2009 Apr; 18(2):123-30. PubMed ID: 19081297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
